Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T12:50:14.410Z Has data issue: false hasContentIssue false
  • English
  • Français

Plasma Levels of Imipramine and Desmethylimipramine during Therapy

Published online by Cambridge University Press:  29 January 2018

J. P. Moody ,
A. C. Tait  and
A. Todrick
J. P. Moody
Affiliation:
Department of Clinical Research, Crichton Royal, Dumfries; Royal Dundee Liff Hospital, by Dundee
A. C. Tait
Affiliation:
Crichton Royal, Dumfries
A. Todrick
Affiliation:
Crichton Royal, Dumfries
Get access Rights & Permissions [Opens in a new window]

Extract

Individual variations in drug metabolism are important factors affecting both toxicity and clinical effectiveness (Brodie, 1964; Kalow, 1965; Price Evans, 1965). In most cases the best available index of the drug concentration at the site of action is the plasma level. An estimate of this will show whether the optimal concentration is present and in some cases may indicate whether new symptoms can be attributed to toxic side reactions.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 113 , Issue 495 , February 1967 , pp. 183 - 193
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angst, J. (1961). “A clinical analysis of the effects of Tofranil in depression. Longitudinal and follow-up studies. Treatment of blood relations.” Psychopharmacologia (Berl.), 2, 381–407.CrossRefGoogle ScholarPubMed
Angst, J. (1964). “Antidepressiver Effekt und genetische Faktoren.” Arzneimittel-Forsch. 14, 496–500.Google Scholar
Bernhard, K., and Beer, H. (1962). “Aktivitäten der Expirations-kohlensäure des ZNS und andere Organe nach gaben von 14C-signiertem N-(γ-Dimethyl-aminopropyl)-iminodibenzyl (Psychopharmakon Tofranil) an Ratten und Hunde.” Helv. Physiol. Acta., 20, 114–121.Google Scholar
Brodie, B. B. (1964). “Distribution and fate of drugs: therapeutic implications.” In: Absorption and Distribution of Drugs (ed. Binns, T. B.). Edinburgh: E. & S. Livingstone.Google Scholar
Brodie, B. B., Dick, P., Kielholz, P., Poldinger, W., and Theobald, W. (1961). “Preliminary pharmacological and clinical results with DMI (G. 35020) a metabolite of imipramine.” Psychopharmacologia (Berl.), 2, 467–474.CrossRefGoogle ScholarPubMed
Dingell, J. V., Sulser, F., and Gillette, J. R. (1964). “Species differences in the metabolism of imipramine and desmethylimipramine.” J. Pharmacol. exp. Ther., 143, 14–22.Google Scholar
Edwards, G. (1965). “Comparison of the effect of imipramine and desipramine on some symptoms of depressive illness.” Brit. J. Psychiat., 111, 889–897.CrossRefGoogle ScholarPubMed
Fessler, J. H., and Galley, H. (1964). “Thin-layer chromatography of relatively voluminous samples.” Nature, 201, 1056.Google Scholar
Gillette, J. R. (1965). “Reversible binding as a complication in relating the in vitro effect of drugs to their in vivo activity.” In: Drugs and Enzymes: Second International Pharmacological Meeting. Vol. 4. (ed. Brodie, B. B., and Gillette, J. R.). Oxford: Pergamon Press.Google Scholar
Haydu, G. G., Dhrymiotis, A., and Quinn, G. P. (1962). “Plasma imipramine levels in syndromes of depression.” Amer. J. Psychiat., 119, 574–575.CrossRefGoogle ScholarPubMed
Herrmann, B. (1963). “Quantitative Methoden zur Untersuchung des Stofrwechsels von Tofranil.” Helv. Physiol. Acta, 21, 402–408.Google Scholar
Herrmann, B. (1964). “Untersuchungen über den Stoffwechsel von 4–3-Dibenzo(b,f)azapin-5-yl)propyl-1-(2-hydroxypiperazin dihydrochlorid.” Arzneimittel-Forsch., 14, 219–221.Google Scholar
Herrmann, B., and Pulver, R. (1960). “Der Stoffwechsel des Pharmakons Tofranil: 1 Mitteilung.” Arch. int. Pharmacodyn., 126, 454–469.Google Scholar
Kalow, W. (1965). “Individual variation in drug metabolism as cause of drug toxicity.” In: Drugs and Enzymes: Second International Pharmacological Meeting. Vol. 4. (ed. Brodie, B. B., and Gillette, J. R.). Oxford: Pergamon Press.Google Scholar
Kuhn, R. (1958). “The treatment of depressive states with G.22355 (Imipramine hydrochloride).” Amer. J. Psychiat., 115, 459–464.Google Scholar
Leybold, K., and Staudinger, H. (1962). “Hydroxylierung von Phenylbutazon und Imipramin durch Kaninchenlebermikrosomen.” Z. Ges. exp. Med., 136, 78–85.Google Scholar
Pare, C. M. B., Rees, L., and Sainsbury, M. J. (1962). Differentiation of two genetically specific types of depression by the response to antidepressants.” Lancet, ii, 1340–1343.Google Scholar
Price Evans, D. A. (1965). “Individual variations in drug metabolism as a factor in drug toxicity.” Ann. N.Y. Acad. Sci., 123 (1), 178–187.CrossRefGoogle Scholar
Sulser, F., Watts, J., and Brodie, B. B. (1962). “On the mechanism of anti-depressant action of imipramine-like drugs.” Ann. N.Y. Acad. Sci., 96, (1), 279–286.Google Scholar
Yates, C. M., Todrick, A., and Tait, A. C. (1963). “Aspects of the clinical chemistry of desmethylimipramine in man.” J. Pharm. Pharmacol., 15, 432–439.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.